Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Haifa Zaibi (Tunis, Tunisia), Haifa Zaibi, Lamia Missaoui, Jihen Ben Amar, Nada Fezai, M. Ali Baccar, Salwa Azzebi, Besma Dhahri, Hichem Aouina. Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors?. Eur Respir J 2016; 48: Suppl. 60, 1549

Member's Comments

No comment yet.

Related content which might interest you: Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Should pseudomonas aeruginosa be the main target in bronchiectasis? Source: International Congress 2016 – Monitoring comorbidities Year: 2016 A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Bronchiectasis exacerbations by Pseudomonas aeruginosa: differences and similarities Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Source: Eur Respir J 2006; 28: 974-979 Year: 2006 LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Atorvastatin as novel treatment in bronchiectasis patients colonized with pseudomonas aeruginosa Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Pseudomonas aeruginosa infection and exacerbations in bronchiectasis: more questions than answers Source: Eur Respir J, 51 (2) 1702497; 10.1183/13993003.02497-2017 Year: 2018 COPD and pseudomonas aeruginosa, an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Could nan1-expression and production by pseudomonas aeruginosa be a prognostic factor for survival in CF patients Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018